Q-omics provides the consensus-scored BEND2 profile across patient tissues and cancer cell-line models. BEND2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, BEND2 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, BEND2 RNA expression shows 6,741 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, LUSC, and STAD as cancer lineages where BEND2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BEND2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BEND2 survival associations across molecular data types. BEND2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BEND2 RNA expression–survival associations across cancer types. High BEND2 expression shows unfavorable associations in KICH, ACC, UVM and OV, but favorable associations in MESO and PRAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for BEND2 RNA expression.
This table summarizes BEND2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for BEND2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BEND2 shows lower tumor expression in LUSC, LUAD, BRCA, KICH, THCA and LIHC. The LUSC box plot shows higher BEND2 RNA expression in normal versus tumor tissue (log2 FC = −0.127, t-test p < 0.001).
This table shows molecular features associated with BEND2 in patient tissues and cancer cell lines. In patient samples, BEND2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, BEND2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
